Shares of ImmunoGen, Inc. (NASDAQ:IMGN) have been given an average rating of “Buy” by the eleven analysts that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $14.75.
A number of equities analysts have issued reports on the stock. ValuEngine raised shares of ImmunoGen from a “hold” rating to a “buy” rating in a report on Wednesday. HC Wainwright set a $18.00 target price on ImmunoGen and gave the stock a “buy” rating in a research note on Monday, October 8th. Zacks Investment Research upgraded ImmunoGen from a “sell” rating to a “hold” rating in a research note on Monday, September 24th. Guggenheim started coverage on ImmunoGen in a research note on Monday, September 17th. They set a “buy” rating on the stock. Finally, Piper Jaffray Companies started coverage on ImmunoGen in a research note on Thursday, September 6th. They set an “overweight” rating on the stock.
In other news, VP Anna Berkenblit sold 5,851 shares of ImmunoGen stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $8.00, for a total transaction of $46,808.00. Following the sale, the vice president now directly owns 132,769 shares in the company, valued at approximately $1,062,152. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.44% of the company’s stock.
IMGN traded down $0.36 during mid-day trading on Friday, reaching $7.43. 1,577,000 shares of the stock were exchanged, compared to its average volume of 2,602,897. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.76 and a quick ratio of 5.73. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -9.91 and a beta of 1.96. ImmunoGen has a 1 year low of $4.80 and a 1 year high of $13.41.
ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings data on Friday, July 27th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.02). The business had revenue of $9.29 million for the quarter, compared to analysts’ expectations of $14.12 million. ImmunoGen’s revenue was down 76.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.10) earnings per share. As a group, equities analysts anticipate that ImmunoGen will post -1.22 EPS for the current year.
ImmunoGen Company Profile
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.